Association between spatial distribution of leukocyte subsets and clinical presentation of head and neck squamous cell carcinoma.
PD-L1
dendritic cell
head and neck cancer
leucocyte subsets
multiplex immunohistochemistry
spatial distribution
tumor microenvironment
tumor-associated macrophage
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
06
2023
accepted:
28
12
2023
medline:
8
2
2024
pubmed:
7
2
2024
entrez:
7
2
2024
Statut:
epublish
Résumé
Interactions between tumor cells and cells in the microenvironment contribute to tumor development and metastasis. The spatial arrangement of individual cells in relation to each other influences the likelihood of whether and how these cells interact with each other. This study investigated the effect of spatial distribution on the function of leukocyte subsets in the microenvironment of human head and neck squamous cell carcinoma (HNSCC) using multiplex immunohistochemistry (IHC). Leukocyte subsets were further classified based on analysis of two previously published HNSCC single-cell RNA datasets and flow cytometry (FC). IHC revealed distinct distribution patterns of leukocytes differentiated by CD68 and CD163. While CD68hiCD163 The distribution patterns and their distinct interactions via the PD-L1/PD-1 pathway suggest divergent roles of CD68/CD163 subsets in the HNSCC microenvironment. PD-L1/PD-1 interactions appear to occur primarily between specific cell types close to the tumor site. Whether PD-L1/PD-1 interactions have a positive or negative impact on patient survival appears to depend on both the spatial localization and the entity of the interacting cells. Co-expression of other markers, particularly CD80 and CD206, supports the hypothesis that CD68/CD163 IHC subsets have distinct functions. These results highlight the association between spatial leukocyte distribution patterns and the clinical presentation of HNSCC.
Sections du résumé
Background
Interactions between tumor cells and cells in the microenvironment contribute to tumor development and metastasis. The spatial arrangement of individual cells in relation to each other influences the likelihood of whether and how these cells interact with each other.
Methods
This study investigated the effect of spatial distribution on the function of leukocyte subsets in the microenvironment of human head and neck squamous cell carcinoma (HNSCC) using multiplex immunohistochemistry (IHC). Leukocyte subsets were further classified based on analysis of two previously published HNSCC single-cell RNA datasets and flow cytometry (FC).
Results
IHC revealed distinct distribution patterns of leukocytes differentiated by CD68 and CD163. While CD68hiCD163
Conclusion
The distribution patterns and their distinct interactions via the PD-L1/PD-1 pathway suggest divergent roles of CD68/CD163 subsets in the HNSCC microenvironment. PD-L1/PD-1 interactions appear to occur primarily between specific cell types close to the tumor site. Whether PD-L1/PD-1 interactions have a positive or negative impact on patient survival appears to depend on both the spatial localization and the entity of the interacting cells. Co-expression of other markers, particularly CD80 and CD206, supports the hypothesis that CD68/CD163 IHC subsets have distinct functions. These results highlight the association between spatial leukocyte distribution patterns and the clinical presentation of HNSCC.
Identifiants
pubmed: 38322012
doi: 10.3389/fimmu.2023.1240394
pmc: PMC10844964
doi:
Substances chimiques
B7-H1 Antigen
0
Programmed Cell Death 1 Receptor
0
RNA
63231-63-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1240394Informations de copyright
Copyright © 2024 Netzer, von Arps-Aubert, Mačinković, von der Grün, Küffer, Ströbel, von Knethen, Weigert and Beutner.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Oral Oncol. 2020 Jul;106:104723
pubmed: 32315971
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Oral Oncol. 2019 Jun;93:66-75
pubmed: 31109698
Cell Immunol. 2013 Jan;281(1):51-61
pubmed: 23454681
Front Immunol. 2018 Jul 30;9:1774
pubmed: 30105035
Cell. 2020 Jul 23;182(2):497-514.e22
pubmed: 32579974
Crit Rev Oncol Hematol. 2022 Jan;169:103569
pubmed: 34890800
Lab Invest. 2017 Jan;97(1):4-13
pubmed: 27869795
Cell. 2015 Sep 10;162(6):1242-56
pubmed: 26359984
Nat Methods. 2021 Sep;18(9):997-1012
pubmed: 34341583
Nat Rev Immunol. 2019 Jun;19(6):369-382
pubmed: 30718830
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Cancer Commun (Lond). 2020 Apr;40(4):135-153
pubmed: 32301585
Cancer Immunol Immunother. 2021 Sep;70(9):2545-2557
pubmed: 33569630
Sci Immunol. 2022 Apr;7(70):eabi5072
pubmed: 35363543
J Leukoc Biol. 2022 Jul;112(1):173-184
pubmed: 34811790
Nature. 2017 May 25;545(7655):495-499
pubmed: 28514441
Immunity. 2019 Sep 17;51(3):573-589.e8
pubmed: 31474513
Science. 2011 Aug 26;333(6046):1157-60
pubmed: 21798893
Methods. 2014 Nov;70(1):46-58
pubmed: 25242720
Science. 2011 Aug 26;333(6046):1154-7
pubmed: 21798897
Genome Biol. 2019 Dec 23;20(1):296
pubmed: 31870423
Scand J Immunol. 2008 May;67(5):453-63
pubmed: 18405323
Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6640-6650
pubmed: 32161124
Nat Rev Immunol. 2008 Dec;8(12):958-69
pubmed: 19029990
Cell. 2021 Jun 24;184(13):3573-3587.e29
pubmed: 34062119
Tumour Biol. 2015 Jul;36(7):5291-8
pubmed: 25666753
Nat Rev Dis Primers. 2020 Nov 26;6(1):92
pubmed: 33243986
Nat Commun. 2021 Dec 17;12(1):7338
pubmed: 34921143
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Int J Clin Exp Pathol. 2013;6(4):561-70
pubmed: 23573303
Am J Respir Cell Mol Biol. 2015 Nov;53(5):676-88
pubmed: 25870903
Clin Cancer Res. 2022 Mar 01;28(5):1038-1052
pubmed: 34965946
Front Immunol. 2021 Oct 28;12:769534
pubmed: 34777389
JAMA Otolaryngol Head Neck Surg. 2021 Oct 1;147(10):871-878
pubmed: 34473219
Front Oral Health. 2021 Jun 23;2:676643
pubmed: 35048023
Cancer Biol Ther. 2020;21(2):139-146
pubmed: 31698994
Genome Biol. 2016 Feb 17;17:29
pubmed: 26887813
Pathol Oncol Res. 2020 Jul;26(3):1687-1695
pubmed: 31606786
PLoS One. 2012;7(8):e42656
pubmed: 22880072
Cancer Discov. 2013 Jul;3(7):770-81
pubmed: 23619168
Lancet Oncol. 2016 Jul;17(7):956-965
pubmed: 27247226
Cancer Sci. 2020 Oct;111(10):3426-3434
pubmed: 32726495
Immunity. 2020 Jan 14;52(1):183-199.e9
pubmed: 31924475
Cancers Head Neck. 2020 Mar 16;5:4
pubmed: 32195008
Nat Commun. 2023 May 10;14(1):2692
pubmed: 37164975
Nat Immunol. 2020 Apr;21(4):442-454
pubmed: 32152508
J Transl Med. 2023 Mar 27;21(1):223
pubmed: 36973787
Folia Histochem Cytobiol. 2020;58(1):17-24
pubmed: 32176313
Biomed Res Int. 2014;2014:838632
pubmed: 24883329
Nat Commun. 2022 Apr 13;13(1):1983
pubmed: 35418195
Int J Mol Sci. 2020 Jul 31;21(15):
pubmed: 32752088
Front Oncol. 2022 Sep 28;12:1000447
pubmed: 36237305
Mol Carcinog. 2020 Jul;59(7):766-774
pubmed: 32017286